<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82985">
  <stage>Registered</stage>
  <submitdate>23/07/2008</submitdate>
  <approvaldate>25/08/2008</approvaldate>
  <actrnumber>ACTRN12608000424303</actrnumber>
  <trial_identification>
    <studytitle>Antibtiotics for Asymptomatic Acute Otitis Media</studytitle>
    <scientifictitle>A double blind placebo-controlled randomized clinical trial of the use of oral azithromycin in Aboriginal children between 6 months and 30 months of age presenting with asymptomatic acute otitis media without perforation</scientifictitle>
    <utrn />
    <trialacronym>AAAOM</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Acute otitis media without perforation</healthcondition>
    <conditioncode>
      <conditioncode1>Ear</conditioncode1>
      <conditioncode2>Other ear disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two doses of 30mg/kg of azithromycin or the placebo will be adminstered a week a apart on Day 0 and Day 7. The mode of administration of the drug will be oral suspension.</interventions>
    <comparator>The placebo is custom made to smell, taste and imitate azithromycin.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical failure (All): Proportion of children with bulging or middle ear discharge at 14 days or withdrawn due to complications or side effects. All children who are lost to follow up are considered clinical failures.</outcome>
      <timepoint>14 days after commencement of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of two treatment groups for proportion of children with unresolved bulging at 7 days (on treatment assessment)</outcome>
      <timepoint>Day 7 after commencement of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of two treatment groups for proportion of children with unresolved bulging at 30 days (end of follow up assessment)</outcome>
      <timepoint>Day 30 after commencement of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of children with bulging or middle ear discharge or withdrawn due to complications or side effects. Not including children who are lost to follow up.</outcome>
      <timepoint>Day 0, 7, 14 and 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of children who develop an illness requiring additional medical treatment</outcome>
      <timepoint>Day 0, 7, 14 and 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of children who develop an illness requiring cessation of prescribed antibiotics</outcome>
      <timepoint>Between Day 0 and day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of children who have no improvement in other conditions recorded like skin sores and rhinosinusitis</outcome>
      <timepoint>Day 7, 14 and 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Microbiological outcomes including carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae</outcome>
      <timepoint>Day 0, 7, 14 and 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Informed consent obtained and signed

2. All Aboriginal children aged 6 months and 30 months of age on the date of randomisation who are resident in participating communities will be eligible to be screened for asymptomatic acute otitis media without perforation.  

3. The following inclusion criteria for the randomized controlled trial (RCT) will be applied to children diagnosed with asymptomatic acute otitis media:
a.) A bulging tympanic membrane.
b.) No associated symptoms at the time of diagnosis (including ear pain or fever).

4. Children who have a diagnosis of asymptomatic acute otitis media who are able to attend the clinic for follow up visits at day 7, day 14 and day 28.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Acute otitis media with ear pain or fever
2. Acute otitis media with recent onset of perforation and discharge (within 7 days)
3. Chronic suppurative otitis media
4. Previously been randomised into this study
5. Have received antibiotics in the previous 7 days (not including topical antibiotics)
6. A more severe illness requiring antibiotics
7. Azithromycin allergy 
8. Immunodeficiency</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment procedures: The random assignment to treatment is kept in a series of sequentially numbered sealed opaque envelopes. Once a child has met the eligibility criteria and the parent/carer signed the consent form, the next sequentially numbered sealed opaque is opened by the study project officer.</concealment>
    <sequence>This random sequence is computer generated (Stata Version 8.0) by the IT Division of the Menzies School of Health Research</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>31/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Menzies School of Health Research</primarysponsorname>
    <primarysponsoraddress>Royal Darwin Hospital Campus,
Casuarina, NT 0810</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Queensland Institute of Medical Research</sponsorname>
      <sponsoraddress>300 Herston Road
Herston
QLD 4006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to evaluate whether azithromycin compared with no treatment results in a reduction in the proportion of children with signs of persistent disease 14 days after starting treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Human Research Ethics Committee of NT Department of Health and Families and Menzies School of Health Research</ethicname>
      <ethicaddress>Menzies School of Health Research 
PO Box 41096
Casuarina NT 0810</ethicaddress>
      <ethicapprovaldate>11/09/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/07/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andre Wattiaux</name>
      <address>Menzies School of Health Research
POBox 41096
Casuarina NT 0811</address>
      <phone>0889228649</phone>
      <fax />
      <email>andre.wattiaux@menzies.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Andre Wattiaux</name>
      <address>Menzies School of Health Research
POBox 41096
Casuarina NT 0811</address>
      <phone>0889228649</phone>
      <fax />
      <email>andre.wattiaux@menzies.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Andre Wattiaux</name>
      <address>Menzies School of Health Research
POBox 41096
Casuarina NT 0811</address>
      <phone>0889228649</phone>
      <fax />
      <email>andre.wattiaux@menzies.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>